Previous Close | 34.99 |
Open | 34.98 |
Bid | 38.10 x N/A |
Ask | 38.53 x N/A |
Day's Range | 34.92 - 37.86 |
52 Week Range | 29.97 - 89.58 |
Volume | |
Avg. Volume | 2 |
Market Cap | N/A |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | Feb 22, 2023 - Feb 27, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for 38I.DU
To many investors, gene editing sounds like the plot of a science fiction movie. The concept of being able to edit our DNA to cure genetic diseases is quite unbelievable, and the upside of gene editing to treat rare diseases is impressive. However, many gene editing stocks are making waves, looking to advance toward eradicating cancer and other serious illnesses. But ever since 2012, gene editing has been a reality, at least in terms of having the technology needed to edit genes. Don’t get me wr
Gene editing stocks present themselves as one of the more lucrative investments in the healthcare sector. Gene editing, a revolutionary take on the science of genetic engineering, has the potential to countless lives around the globe. By introducing genetic material into cells, scientists can correct genetic abnormalities in a way never seen before. With the potential for vast improvements, gene therapy and gene editing are promising modern biotechnology forms.InvestorPlace - Stock Market News,
Cathie Wood is beating the market again so far in 2023, and that leaves growth investors wondering if she can recapture her 2020 performance in a bottle. Ark puts out daily transaction reports, so we know what Wood is buying and selling. Tesla bears think they're winning with the stock down 65% since hitting all-time highs in late 2021.